TrialCancer medicine2023

Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.

Elisabeth G E de Vries et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.